[A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus].
OBJECTIVE
To evaluate the efficacy and safety of 30 mg slow-release-gliclazide (Diamicron MR) on type 2 diabetes patients with the level of blood glucose poorly controlled formerly.


METHODS
154 type 2 diabetes patients with the level of blood glucose poorly controlled formerly were enrolled and treated with Diamicron MR for 16 weeks. The efficacy of slow-release-gliclazide was evaluated through HbA1c, FPG and 2 h PBG after 16 weeks of treatment period. The safety was evaluated through the adverse events including hypoglycemic episodes and the change of vital signs and clinic laboratory parameters.


RESULTS
After 16 weeks of treatment period, the HbA1c, FPG and 2 h PBG were decreased by 1.89%, 2.31 mmol/L and 3.94 mmol/L respectively, cutting down 21.6%, 24.5% and 27.8% relatively in comparison with pre-treatment. Glucose metabolism could be significantly improved by taking once-daily Diamicron MR.


CONCLUSIONS
Slow-release-gliclazide offers the significant treatment safely, which is important to optimize type 2 diabetes mellitus management.
Jia
Wei-ping
WP
Shanghai Diabetes Institute, Department of Endocrinology & Metabolism, Shanghai No.6 People's Hospital Affiliated to Jiaotong University, Shanghai 200233, China.
Ning
Guang
G
Gao
Xin
X
Yan
Li
L
Yang
Hua-zhang
HZ
Li
Ming
M
Hong
Jie
J
Lu
Zhi-qiang
ZQ
Cheng
Hua
H
Qi
Yi-qin
YQ
Li
Zhong-wen
ZW
Xiang
Kun-san
KS
D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D005907:Gliclazide